MediWound completes recruitment for Phase III trial

MediWound's burns treatment uses chemical methods rather than surgical techniques.

MediWound Ltd., which is developing a gel for the treatment of burns, has completed recruitment of the 175 patients required to file the intermediary report for its Phase III clinical trial for European Medicines Agency (EMEA) approval.

Nochi Dankner's IDB Holding Corp. (TASE:IDBH) unit Clal Biotechnology Industries Ltd. (TASE: CBI) owns 56% of MediWound.

MediWound should publish its intermediary report by the end of the year. If the results show that the trial has clearly statistically achieved its main targets, then MediWound will be exempt from recruiting an additional 100 patients in order to provide clear statistical proof in a larger sample of recipients of the treatment. Should that happen then the clinical trial will take an extra year.

MediWound is striving to prove that its gel can remove burned and superfluous tissues utilizing a precise and efficient chemical method, instead of current surgical techniques.

Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA; TASE:TEVA) will be required to increase its holding in MediWound to 25% if the company receives approval for marketing its product in Europe.

Published by Globes [online], Israel business news - - on August 20, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018